A key factor is CX3CL1, a chemokine with soluble and transmembrane species that acts as both a chemoattractant and an adhesion molecule. Thromboxane A2 and its receptor, TP, are also critical to atherogenesis by promoting vascular inflammation and consequent leukocyte recruitment. We examined the effects of TP stimulation on processing and function of CX3CL1, using CX3CL1-expressing human ECV-304 cells and primary human vascular endothelial cells. TP agonists promoted rapid shedding of cell surface CX3CL1, which was inhibited by pharmacological inhibitors or specific small interfering RNA targeting tumor necrosis factor-␣-converting enzyme (TACE). Because it reduced cell surface CX3CL1, we predicted that TP stimulation would inhibit adhesion of leukocytes expressing the CX3CL1 cognate receptor but, paradoxically, saw enhanced adhesion. We questioned whether the enhanced ability of the remaining membrane-associated CX3CL1 to bind targets was caused by changes in its lateral mobility. Using fluorescence recovery after photobleaching, we found that plasmalemmal CX3CL1 was initially tethered but ultimately mobilized by TP agonists. TP stimulation provoked clustering of transmembrane CX3CL1 at sites of contact with adherent leukocytes. These data demonstrate that TP stimulation induces two distinct effects: a rapid cleavage of surface CX3CL1, thereby releasing the soluble chemoattractant, plus mobilization of the remaining transmembrane CX3CL1 to enhance the avidity of interactions with adherent leukocytes. The dual effect of TP allows CX3CL1 to recruit leukocytes to sites of vascular inflammation while enhancing their adhesion once recruited. leukocytes; inflammation; endothelial cells ATHEROSCLEROSIS is a chronic inflammatory disease involving the vascular wall, leukocytes, and platelets. Thromboxane A 2 (TXA 2 ), a prostanoid formed from the metabolism of arachidonic acid via the cyclooxygenase (COX) pathway, has long been implicated in the pathogenesis of atherosclerosis and induces platelet aggregation, vasoconstriction, and vascular smooth muscle cell (VSMC) proliferation (42). It is produced mainly by platelets but also by monocytes/macrophages, VSMC, and endothelial cells (37, 41, 42) . TXA 2 mediates its effects through the thromboxane prostanoid (TP) receptor, a G protein-coupled receptor expressed in diverse hematopoietic cell types, including platelets and monocytes, as well as in endothelial cells, fibroblasts, and VSMC (15, 41). COX inhibitors, which decrease TXA 2 production, protect against vascular inflammation and acute vascular events in patients at high risk (3). Mice deficient in TP or treated with a TP antagonist show markedly decreased leukocyte accumulation within the vascular wall (5, 22).
protein-coupled receptor expressed in diverse hematopoietic cell types, including platelets and monocytes, as well as in endothelial cells, fibroblasts, and VSMC (15, 41) . COX inhibitors, which decrease TXA 2 production, protect against vascular inflammation and acute vascular events in patients at high risk (3) . Mice deficient in TP or treated with a TP antagonist show markedly decreased leukocyte accumulation within the vascular wall (5, 22) .
In atherogenesis, chemokines recruit circulating leukocytes and other cells to the injured vascular wall. The chemokine CX 3 CL1 (fractalkine) plays a key role by recruiting monocytes, T lymphocytes, and other inflammatory cells (6, 24, 28, 29, 32, 40) . Most chemokines are small, secreted proteins. CX 3 CL1 is one of only two chemokines that have soluble and membrane-anchored species (2, 10, 27) . Soluble CX 3 CL1 consists of a chemokine domain and mucin stalk and is released from the plasma membrane following cleavage of the full-length protein by ADAM (a disintegrin and metalloprotease)-10 and ADAM17/TACE (tumor necrosis factor-␣-converting enzyme) metalloproteases (12, 17, 43) . The soluble species thus generated is chemoattractant for monocytes/macrophages, natural killer cells, T lymphocytes, and VSMC, all of which express CX 3 CR1, the unique receptor for CX 3 CL1 (10, 18, 26) .
CX 3 CL1-CX 3 CR1-mediated cellular traffic is critically implicated in coronary atherosclerosis and stroke. In affected coronary arteries, CX 3 CL1 protein expression is increased throughout the vascular wall in endothelium, intima, media, and adventitia (26, 45, 47) . CX 3 CL1 is also expressed in macrophages, foam cells, and VSMC and acts to recruit monocytes, memory T lymphocytes, and additional VSMC to the injured arterial wall (26, 45, 47) . Thus, within the atherosclerotic lesion, CX 3 CL1 is expressed by and can recruit cells capable of secreting large amounts of extracellular matrix proteins, thereby favoring formation of stable atherosclerotic plaques (10, 18, 47) . By recruiting monocytes to the injured vessels, CX 3 CL1 promotes formation of macrophage-rich, unstable plaques. Genetic targeting of CX 3 CL1 or CX 3 CR1 in atherosclerosis-prone mice highly protects them from vascular disease (6, 24, 40) . In humans, gene polymorphisms in CX 3 CR1 that impair leukocyte chemotaxis and binding of the receptor to cell surface CX 3 CL1 protect against myocardial infarction, unstable angina, cardiac death, and stroke (13, 28, 32) .
It is widely recognized that important links exist between the thrombotic events and the vascular inflammation that define atherosclerosis. The precise nature of these links has not yet been well elucidated. TXA 2 , acting through TP, potently in-duces vascular inflammation, promoting leukocyte recruitment to the injured vascular wall. We studied whether TP mediates these effects by enhancing the exposure and activity of the chemokine CX 3 CL1. We found that TP stimulation causes rapid shedding of CX 3 CL1 from the cell surface yet, unexpectedly, promotes enhanced CX 3 CL1-dependent leukocyte adhesion. TP stimulation mobilizes remaining membrane-associated CX 3 CL1, allowing it to cluster at sites of contact with adherent leukocytes. The potential implications of these dual mechanisms of regulation of CX 3 CL1 function by TP for the development of vascular inflammation are discussed.
MATERIALS AND METHODS
Cell culture. ECV-304 cells were obtained from the American Type Culture Collection (Manassas, VA), and the generation of cells expressing green fluorescent protein-tagged CX 3CL1 (ECV-CX3CL1-GFP) or untagged CX3CL1 (ECV-CX3CL1) has been described previously (8, 25) . A cDNA construct encoding mCherry-tagged CX 3CL1 was generated by PCR amplification of full-length CX3CL1 with EcoR1 and BamH1 sites at the NH 2 and COOH terminus, respectively, and subcloning into the corresponding restriction sites of pmCherry-N1 vector (Clontech Laboratories, Mountain View, CA). The resulting CX 3CL1-mCherry cDNA construct was verified by sequencing and was expressed in ECV-304 cells using FuGene HD transfection reagent according to the manufacturer's specifications (Roche Diagnsotics, Laval, PQ, Canada). Cells were grown in DMEM and Ham's F12 (Wisent, St-Bruno, QC, Canada) supplemented with 5% fetal calf serum. Human K562 erythroleukemia cells that stably express CX 3CR1 (K562-CX3CR1) were cultured in RPMI supplemented with HEPES and 10% fetal calf serum (8, 10) . Primary human umbilical vein endothelial cells (HUVEC) were obtained from Clonetics (La Jolla, CA) and cultured in endothelial cell growth medium (Clonetics) (10) . Peripheral blood mononuclear cells (PBMC) were isolated from the blood of healthy volunteers as previously described (8) .
Antibodies and reagents. The following primary antibodies were used: goat anti-human CX 3CL1 (R&D Systems, Minneapolis, MN), rabbit anti-Erk (extracellular signal-related kinase) and rabbit antiphospho-Erk (Cell Signaling Technology, Danvers, MA), mouse anti-actin (Stressgen, Victoria, BC, Canada), mouse anti-GAPDH (Chemicon, Temecula, CA), and mouse anti-Bcr (Santa Cruz Biotechnology, Santa Cruz, CA). Rabbit anti-phospho-c-Raf, rabbit antiphospho-MEK1/2, and rabbit anti-MEK1/2 were all obtained from Cell Signaling Technology. Rabbit anti-c-Raf was obtained from Santa Cruz Biotechnology. Mouse monoclonal antibody (Ab) directed against human TACE was a kind gift of Dr. Roy Black (Amgen, Sherman Oaks, CA). The following secondary antibodies were used: horseradish peroxidase-conjugated anti-mouse, anti-goat and antirabbit IgG, Cy3-and Cy5-conjugated anti-goat IgG, Cy5-conjugated anti-mouse IgG, and phycoerythrin-conjugated anti-goat IgG (Jackson ImmunoResearch Laboratories, Bar Harbor, ME), as well as Alexa488-conjugated anti-mouse IgG (Invitrogen, Burlington, ON, Canada). TP agonists 9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F 2␣ (U46619) and [1S-1␣,2␤(5Z),3␣(1E,3R*),4␣]-7-[3-(3-hydroxy-4-(4=-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid (IBOP), as well as the specific TP antagonist SQ29548 were obtained from Biomol (Plymouth Meeting, PA). The Erk inhibitor U0126 was obtained from LC Laboratories (Woburn, MA). The metalloprotease inhibitors TAPI-2 and GM6001 were obtained from Peptides International (Louisville, KY) and Chemicon International (Temecula, CA), respectively. DNA expression constructs encoding GFP-tagged glycosylphosphatidylinositol (GPI-GFP) and Fc␥RIIa receptor (Fc␥RIIa-GFP) were a gift from Dr. Sergio Grinstein (The Hospital for Sick Children Research Institute, Toronto, ON, Canada), and cells were transfected using FuGene (Roche Diagnostics).
Immunoblotting. SDS-PAGE and immunoblotting were performed, as previously described, using anti-CX 3CL1 Ab (0.2 g/ml) and anti-Erk (0.01 g/ml) or anti-phospho-Erk Ab (0.2 g/ml) (8, 25) . Anti-actin or anti-GAPDH Ab was used to control for protein loading. Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham Biosciences, Little Chalfont, UK) recorded on X-ray film.
Flow cytometry. ECV-CX 3CL1-GFP cells were grown in 10-cm dishes and treated with the TP agonists IBOP or U46619 for various time periods. Cells were lifted by briefly incubating with 5% EDTA at 4°C, washed, and fixed in 4% paraformaldehyde. Cells were incubated with 5% donkey serum followed by anti-CX 3CL1 Ab for 1 h at room temperature. After further washing, cells were incubated with phycoerythrin-conjugated anti-goat IgG for 1 h at room temperature. Cells were suspended in PBS and analyzed using a fluorescenceactivated cell scanner (FACScan; BD Biosciences, San Jose, CA).
Immunofluorescence staining. ECV-CX 3CL1-GFP cells were grown on glass coverslips, fixed using 4% paraformaldehyde, washed, and blocked with 5% donkey serum at room temperature for 1 h. Cells were incubated with anti-CX 3CL1 Ab (2.5 g/ml) and anti-TACE Ab (2.7 g/ml) at room temperature for 1 h followed by Cy3-conjugated anti-goat IgG and Cy5-conjugated anti-mouse IgG for 1 h. Cells were mounted onto glass slides and visualized using a spinning disk DMIRE2 confocal microscope (Leica Microsystems, Toronto, ON, Canada) equipped with a Hamamatsu backthinned charge-coupled device (EM-CCD) camera. Images were acquired using ϫ100 oil immersion and appropriate filters (8, 25) .
Fluorescence recovery after photobleaching. Fluorescence recovery after photobleaching (FRAP) was performed as previously described (8, 25) . Briefly ECV-CX3CL1-GFP cells or ECV-CX3CL1 cells transfected with GPI-GFP or Fc␥RIIa-GFP cDNA were grown on 25-mm coverslips, mounted into Attafluor chambers, and incubated in RPMI containing 5% fetal calf serum and 25 mM HEPES at 37°C (8, 25) . Live cells were analyzed by confocal microscopy. A 30-mW LASOS argon laser was used to irreversibly photobleach the entire juxtanuclear CX3CL1-containing compartment (8, 25) . To prevent potential shedding of cell surface CX3CL1, cells were treated with the metalloprotease inhibitor GM6001 for 4 h before assays were performed. In other experiments, a 2-m region of the plasma membrane was irreversibly photobleached. Recovery of fluorescence was measured over time. Control, nonbleached areas of the plasma membrane of the same cell were also serially monitored to quantify the amount of bleaching caused by repeated image acquisition. Results are expressed as the mean (ϮSE) normalized fluorescence recovery.
Acid-stripping experiments. The rate of delivery of internalized CX3CL1 back to the plasma membrane was assessed as previously described (25, 44) . To prevent potential shedding of cell surface CX3CL1, cells were pretreated with the metalloprotease inhibitor GM6001 before incubation with anti-CX3CL1 Ab for 1 h (43). Membrane-associated Ab was removed by acid wash (0.15M NaCl, 50 mM glycine, 0.1% BSA, pH 2.5) on ice for 2 min and then allowed to recover for various time periods in the presence of TP agonist. Cells were washed, fixed, and incubated with Cy3-conjugated secondary Ab. Images were captured using a Leica DMIRE2 microscope and OpenLab software (Improvision, Lexington, MA). Cell surface immunofluorescence intensity was measured using Volocity imaging software (Improvision, Waltham, MA).
Adhesion assays. Stamper-Woodruff assays were performed as described elsewhere with minor modifications (8, 35, 36) . Briefly, ECV-304, ECV-CX3CL1-GFP, or HUVEC cells were grown to confluence on 25-mm coverslips and treated with the TP agonist IBOP for 30 min. In some experiments, HUVEC were incubated with TNF-␣ (100 U/ml) for 4 h, followed by incubation with function-blocking anti-CX3CL1 Ab (1 g/ml) for 30 min before addition of leukocytes. Control human K562 or K562-CX3CR1 cells were labeled with Alexa555-conjugated cholera toxin to easily visualize them. Cells (5 ϫ 10 5 ) were incubated with either ECV-304 or ECV-CX3CL1-GFP cells using gentle rocking at 10 cycles/min. Nonadherent cells were washed away, and remaining cells were fixed and mounted onto slides. Using a Leica deconvolution microscope, we examined at least 50 high-power fields (ϫ63) to count the number of adherent cells. Results represent the mean values (ϮSE) and were compared using Student's t-test.
To examine localized changes in CX3CL1 expression at the point of contact with adherent leukocytes, ECV-304 cells were plated in six-well plates and grown to 50% confluence. Cells were transfected with CX 3CL1-mCherry cDNA (1.0 g) using FuGene HD (Roche Diagnostics). After 36 h, adhesion assays were performed by incu-bating ECV-CX3CL1-mCherry cells with K562-CX3CR1 cells (5 ϫ 10 5 cells/well) in the presence or absence of IBOP (2.5 g/ml). To prevent inadvertent shedding of CX3CL1 from the plasma membrane, ECV-CX3CL1-mCherry cells in some wells were incubated with the metalloprotease inhibitor GM6001 for 4 h before experiments were performed. To rule out any inadvertent effects of TP stimulation on cell surface expression and mobility of the CX3CL1 receptor CX3CR1, K562-CX3CR1 cells were fixed using 4% paraformaldehyde and washed with glycine (100 mM) in PBS just before adhesion assays were performed. K562-CX3CR1 cells were allowed to adhere for 30 min at 37°C under gentle rocking conditions and then gently washed twice with PBS to remove nonadherent cells. Cells were fixed and permeabilized using 0.1% Triton, and K562-CX3CR1 cells were labeled by incubation with anti-Bcr Ab (2 g/ml) followed by AlexaFluor 488-conjugated anti-mouse IgG secondary Ab (23) . Spinning disk confocal microscopy was performed, and Z-stack images were captured. XY or YZ dimensions of the Z-stack images were used to compare the localized fluorescence intensity CX3CL1-mCherry signal on transfected ECV-304 cells at the point of interface with adherent K562-CX3CR1 cells with the CX3CL1-mCherry fluorescent signal in an adjacent region of similar size in the plasma membrane, where no leukocyte was attached. Fluorescent signals were quantified using ImageJ software (National Institutes of Health), and the ratio of signal intensities between site of contact and site of no contact was measured for 24 randomly chosen cells for each treatment condition. Experiments were performed three separate times.
CX 3CL1 shedding experiments. Small interfering RNA (siRNA) directed against human ADAM10, human TACE, and control nontargeting siRNA were purchased from Santa Cruz Biotechnology. ECV-CX 3CL1 cells were electroporated with siRNA by nucleofection (Amaxa, Gaithersburg, MD) on day 0 and day 2. After the second electroporation, cells were plated in six-well tissue culture plates at a density of 1 ϫ 10 5 cells/well and cultured for 48 h. Cells were incubated with IBOP (2.5 g/ml) for 30 min at 37°C, and conditioned medium was collected. Cells were washed once with PBS and lysed by adding 0.5 ml of RIPA buffer. Protease inhibitor cocktail (Sigma) was added (1:100) to both harvested conditioned medium and cell lysis buffer to prevent protein degradation. Supernatants and cell lysates were cleared by centrifugation at 13,000 rpm at 4°C for 10 min. With the use of fresh samples, CX 3CL1 was detected in conditioned medium and cell lysates using a CX 3CL1 ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's specifications. Three independent experiments were performed, and the data are expressed as the mean (ϮSE) percentage of soluble CX 3CL1 released into the medium in relation to the total amount of CX 3CL1 (soluble and cell associated).
Statistical analyses. The data were analyzed by comparing the mean values using Student's t-test. A value of P Ͻ 0.05 was considered significant.
RESULTS
Stimulation of the TP receptor decreases surface and total levels of CX 3 CL1. When ECV-CX 3 CL1-GFP cells were treated with two distinct TP agonists, total levels of CX 3 CL1, measured by immunoblotting, fell after just 10 min, with the nadir observed at 30 min (Fig. 1, A-C) . When experiments were performed using cells that express untagged CX 3 CL1, TP stimulation provoked a similar fall in the levels of CX 3 CL1 (Fig. 1 , D and E; P Ͻ 0.02). Cell surface CX 3 CL1, measured by flow cytometry, also rapidly fell, reaching minimum levels by 30 min ( Fig. 1F ; P Ͻ 0.05). Although TP stimulation promoted a significant decrease in both total and cell surface CX 3 CL1, the magnitude of the changes was not identical, presumably because the inherent differences in the two methodologies used resulted in a differential ability to detect CX 3 CL1. We further found that the specific TP antagonist SQ29548 prevented loss of CX 3 CL1, verifying the specificity of the response (Fig. 1, G and H) . Thus TP activation promotes reduction of surface and total levels of CX 3 CL1.
TP stimulation induces cleavage of CX 3 CL1 by TACE. We questioned whether TP stimulation results in shedding of CX 3 CL1 from the plasma membrane, a process mediated by ADAM10 and TACE (12, 17, 43) . Consistent with this notion, the metalloprotease inhibitors TAPI-2 and GM6001, which inhibit both ADAM10 and TACE, prevented TP-induced loss of CX 3 CL1 ( Fig. 2A , P Ͻ 0.02; data not shown for GM6001). To verify these findings, we performed immunoblotting using an antibody directed against GFP, conjugated to the cytoplasmic domain of CX 3 CL1 (Fig. 2B) . TP stimulation resulted in loss of full-length CX 3 CL1 (P Ͻ 0.01) and appearance of a small cell-associated species of CX 3 CL1 (P Ͻ 0.01) after shedding of the extracellular domain of the chemokine (Fig.  2B ). These events were prevented by TAPI-2 (Fig. 2B) . To determine whether ADAM10 and/or TACE induced the ob- Fig. 2 . TP stimulation induces cleavage of CX3CL1 by tumor necrosis factor-␣-converting enzyme (TACE). A, top: ECV-CX3CL1 cells were incubated with metalloprotease inhibitor TAPI-2 (10 M for 2 h) and then with IBOP (0.1 g/ml for 30 min), and immunoblotting was performed using anti-CX3CL1 Ab. Blots were stripped and reprobed with anti-actin Ab. Bottom, CX3CL1 band intensities normalized to actin. Values are means Ϯ SE for 4 separate experiments. ¶P Ͻ 0.02. B, top: experiments were performed as described in A, and immunoblotting was performed using anti-GFP Ab. Bottom, proportion of full-length and cleaved CX3CL1 detected for each experimental condition. Values are means Ϯ SE for 3 separate experiments. For full-length and cleaved CX3CL1: P Ͻ 0.01, untreated vs. IBOP; P Ͻ 0.0001, IBOP vs. IBOP ϩ TAPI-2. C: cells were electroporated with TACE small interfering RNA (siRNA), ADAM10 siRNA, or control, nontargeting (scrambled) siRNA on days 0 and 2. After 48 h, cell lysates were harvested, and immunoblotting was performed using anti-TACE and anti-ADAM10 Ab. D: cells were electroporated with the indicated siRNA and incubated with IBOP (30 min), conditioned medium was collected, and cell lysates were harvested. Protease inhibitor cocktail was added to conditioned medium and to cell lysis buffer to prevent protein degradation. Supernatants and cell lysates were cleared by centrifugation. With the use of fresh samples, CX3CL1 was measured using a CX3CL1 ELISA kit (R&D Systems). Values are means Ϯ SE, expressed as the percentage of soluble CX3CL1 released into the conditioned medium relative to the total amount of CX3CL1 (soluble and cell associated), for 3 separate experiments. *P Ͻ 0.03. E: cells were incubated with IBOP (5 min), and cell surface CX3CL1 and TACE were immunofluorescently labeled. Images at right show a magnified view of the indicated areas. Colocalization between CX3CL1 and TACE was assessed using Volocity software. Representative photographs show 16 cells from 3 independent experiments. F: cells were incubated with PMA (1 M), U46619, or IBOP for 30 min, cell lysates were harvested, and immunoblotting was performed using anti-phospho-Erk Ab. To control for protein loading, blots were stripped and reprobed with anti-Erk Ab and anti-actin Ab. Phospho-Erk band intensities were normalized to total Erk. Values are means Ϯ SE for 3 separate experiments. *P Ͻ 0.01 vs. control. G: cells were incubated with PMA or IBOP, and immunoblotting was performed using anti-phospho-MEK1/2 and anti-phospho-c-Raf Ab. Blots were stripped and reprobed with anti-MEK1/2 Ab and anti-c-Raf Ab. Phospho-MEK1/2 and phospho-c-Raf band intensities were normalized to total MEK1/2 and total c-Raf, respectively. served proteolysis of CX 3 CL1, we used siRNA to selectively knock down expression of each protease (Fig. 2C ) and measured soluble levels of CX 3 CL1 generated. In the presence of nontargeting siRNA or ADAM10 siRNA, TP stimulation promoted release of soluble CX 3 CL1 (Fig. 2D , P Ͻ 0.03). In the absence of TACE, TP failed to promote shedding of CX 3 CL1 (Fig. 2D) . In keeping with these observations, CX 3 CL1 and TACE, which did not colocalize on the cell surface under basal conditions, coassociated after 5 min of TP stimulation, yielding a Pearson's correlation coefficient (r) greater than 0.5 ( Fig. 2E ; basal: r ϭ 0.429 Ϯ 0.042, P Ͼ 0.05; IBOP: r ϭ 0.645 Ϯ 0.031, P Ͻ 0.01). After TP stimulation, the increase in soluble CX 3 CL1 detected in the medium was not the same as the decrease in the amount of cell-associated chemokine. Although the magnitude of the individual changes is statistically significant, there is likely differential sensitivity of the two assays used to detect soluble and cell-associated CX 3 CL1 present. It is further possible that some of the soluble CX 3 CL1 released by proteolytic shedding could be bound to the surface of cells or to the underlying extracellular matrix, resulting in a failure to detect it by ELISA.
Since TP can activate a number of signaling pathways, we studied the intracellular mechanisms whereby TP causes shedding of CX 3 CL1. TP promoted rapid phosphorylation of Erk ( Fig. 2F , P Ͻ 0.01) and its upstream effectors, MEK1/2 ( Fig.  2G , P Ͻ 0.01) and c-Raf (Fig. 2G , P Ͻ 0.05) (7). Erk inhibition prevented TP-induced loss of surface CX 3 CL1 (Fig. 2H , P Ͻ 0.05). Overall, TP stimulation causes cleavage of plasmalemmal CX 3 CL1 by TACE, rather than by ADAM10.
TP stimulation does not affect recycling of CX 3 CL1. Because CX 3 CL1 recycles between the plasma membrane and an endocytic compartment, we questioned whether TP stimulation might redistribute the chemokine from the superficial to the intracellular pool (25) . To prevent inadvertent shedding of CX 3 CL1 from the cell surface, cells were preincubated with GM6001 and endocytosis was examined by FRAP, irreversibly photobleaching the entire CX 3 CL1-containing intracellular compartment, as previously described (25, 43) . Recovery of fluorescence, an index of internalization of CX 3 CL1 from the plasma membrane, was recorded over time (25) . Fluorescence of the plasma membrane pool remained largely unaffected by the bleaching procedure and was also monitored. Figure 3 depicts a cell before, immediately after, and 5 min after bleaching. Note that the plasmalemmal fluorescence decreased as the juxtanuclear fluorescence recovered, consistent with delivery of unbleached CX 3 CL1-GFP from the former to the latter compartment. The juxtanuclear CX 3 CL1-GFP compartment recovered to 21.5 Ϯ 3.1% of its original fluorescence by 170 s and was unchanged by TP stimulation (Fig. 3D) .
To test whether TP stimulation affects delivery of internalized CX 3 CL1 back to the plasma membrane, shedding of the chemokine was inhibited using GM6001, and the endomembrane pool was loaded by incubation with CX 3 CL1 Ab at 37°C. Ab bound to the surface was stripped by a short exposure to an acidic solution. Cells were allowed to recover, and reinsertion of CX 3 CL1 in the plasma membrane was determined by quantifying the reappearance of Ab (25) . Fluorescence at the cell surface increased progressively after acid stripping, confirming that CX 3 CL1 within the endomembrane compartment traffics back to the plasma membrane (Fig. 4, A-E, P Ͻ 0.02). TP stimulation did not affect this traffic (compare Fig. 4, C and D; Fig. 4E) .
TP stimulation enhances, not inhibits, CX 3 CL1-dependent leukocyte adhesion. We predicted that TP stimulation, which induces rapid loss of CX 3 CL1 from the cell surface, would impair adhesion of CX 3 CR1-expressing leukocytes. Minimal binding of K562 cells, which do not express CX 3 CR1, to either ECV-304 or ECV-CX 3 CL1-GFP cells was seen (data not shown). Likewise, there was very little adhesion of K562-CX 3 CR1 cells to ECV-304 cells, which do not express CX 3 CL1 (Fig. 5A) (10) . K562-CX 3 CR1 leukocytes effectively adhered to ECV-CX 3 CL1-GFP cells (Fig. 5A) . The presence of plasmalemmal CX 3 CL1 increased leukocyte adhesion fourfold ( Fig. 5A , P Ͻ 0.0000001). Unexpectedly, TP stimulation increased rather than decreased adhesion of K562-CX 3 CR1 leukocytes to ECV-CX 3 CL1-GFP cells (Fig. 5A , P Ͻ 0.05). TP stimulation did not increase adhesion of K562-CX 3 CR1 cells to untransfected ECV-304 cells, ruling out upregulated levels of other adhesion molecules as the cause of the enhanced leukocyte binding observed (Fig. 5A) (10) .
To verify that the observed responses were not an idiosyncratic feature of the transformed cell lines, we performed experiments performed using primary human vascular endothelial cells. Upon TNF-␣ stimulation, endogenous expression of CX 3 CL1 increased fivefold (Fig. 5B, P Ͻ 0.01) . TP stimulation caused a rapid fall in total levels of CX 3 CL1 (Fig. 5B,   Fig. 3 . TP stimulation does not alter endocytosis of CX3CL1. ECV-CX3CL1-GFP cells were grown on glass coverslips and incubated for 4 h with the metalloprotease inhibitor GM6001 (20 M) to prevent inadvertent shedding of CX3CL1 from the cell surface. Cells were incubated with U46619 (20 M) for 30 min, and with an argon laser and scanning confocal microscope, the entire juxtanuclear CX3CL1-containing compartment was irreversibly photobleached, and recovery of fluorescence was determined at 5-to 200-s intervals. To control for inadvertent photobleaching associated with serial image acquisition, nonbleached areas in the plasma membrane were serially observed in parallel. The same cell is shown before bleaching (A), immediately after photobleaching (B), and 5 min later (C). D: at each time point, the ratio of the fluorescence intensity of the internal compartment to the mean control membrane fluorescence intensity was calculated. Each point represents the mean Ϯ SE for at least 6 separate experiments. Scale bar, 14 m. P Ͻ 0.05). In keeping with these results, TP stimulation significantly enhanced proteolytic release of soluble CX 3 CL1 (P Ͻ 0.005, Fig. 5C ). The enhanced shedding of CX 3 CL1 was prevented when activation of TACE was blocked (P Ͻ 0.005, Fig. 5C ). When HUVEC were incubated with TNF-␣, adhesion of K562-CX 3 CR1 cells increased by 30% ( Fig. 5D ; P Ͻ 0.005). In this instance, preincubation of endothelial cells with specific function-blocking anti-CX 3 CL1 Ab significantly decreased the number of bound leukocytes (Fig. 5D , P Ͻ 0.05). Similarly, TNF-␣ activation increased binding of primary PBMC 10-fold ( Fig. 5E , P Ͻ 0.001). Although TP stimulation resulted in loss of cell-associated CX 3 CL1, K562-CX 3 CR1 cell adhesion increased by 70% (Fig. 5D , P Ͻ 0.005) and PBMC adhesion increased by 50% (Fig. 5E , P Ͻ 0.001). Preincubation of endothelial cells with anti-CX 3 CL1 Ab prevented TPinduced leukocyte adhesion, confirming the observed increase in binding was CX 3 CL1 dependent (Fig. 5D , P Ͻ 0.01; Fig.  5E , P Ͻ 0.001). Using a specific antagonist of TP, SQ29548, we verified that the observed increase in leukocyte adhesion was directly related to TP stimulation ( Fig. 5F , P Ͻ 0.005). Blocking activation of TACE using the Erk inhibitor U0126 also prevented TP-induced increase in leukocyte adhesion ( Fig.  5F , P Ͻ 0.001). Together, these data demonstrate that TP stimulation increases leukocyte adhesion to cell surface CX 3 CL1 despite reducing the overall amount of the chemokine present on the plasma membrane.
TP stimulation mobilizes plasmalemmal CX 3 CL1 and induces clustering of CX 3 CL1 at sites of contact with adherent leukocytes. In principle, increased leukocyte binding to CX 3 CL1 could occur despite reduced CX 3 CL1 levels if TP stimulation mobilized and redistributed plasmalemmal CX 3 CL1, allowing the chemokine to move to sites of contact with CX 3 CR1 on leukocytes. TP stimulation could thereby increase the overall avidity of ligand-receptor interactions, strengthening adhesion between CX 3 CR1-expressing leukocytes and CX 3 CL1-expressing adherent cells.
To test this notion, an area of CX 3 CL1-GFP in the plasma membrane was irreversibly photobleached and recovery of fluorescence was serially observed (Fig. 6A, prebleaching; Fig. 6B , immediately after bleaching; Fig. 6C , 5 min after bleaching). As a control, CX 3 CL1-expressing cells were transfected with cDNA encoding freely mobile GPI-GFP, and recovery of fluorescence was similarly observed (Fig. 6, D-F) . CX 3 CL1-GFP fluorescence recovered poorly compared with GPI-GFP (Fig. 6, G and H) . For CX 3 CL1-GFP, only 25.8 Ϯ 2.6% of fluorescence of the bleached area recovered after 60 s, compared with 85.0 Ϯ 2.9% of GPI-GFP (Fig. 6H) . As another control, ECV-CX 3 CL1 cells were transfected with DNA encoding the single transmembrane-spanning protein, Fc␥RIIA, conjugated to GFP (Fc␥RIIA-GFP). Fc␥RIIA receptors were highly mobile, as indicated by the rapid and near complete recovery of fluorescence after photobleaching (Fig. 6H ). These data demonstrate that lateral diffusion of transmembrane CX 3 CL1 within the membrane is highly impeded, rendering the chemokine largely immobile.
IBOP treatment significantly enhanced mobility of plasmalemmal CX 3 CL1, resulting in fluorescence recovery of 48.2 Ϯ 6.2% at 55 s postbleaching, compared with 26.3 Ϯ 2.5% recovery in the absence of IBOP (Fig. 6G , P Ͻ 0.05). After TP-induced ectodomain shedding of CX 3 CL1, we reasoned that it might not be possible to distinguish between reappearance of GFP fluorescence due to movement of full-length CX 3 CL1 or to movement of any COOH-terminal cleavage fragments retained within the plasma membrane. To prevent potential shedding of CX 3 CL1, cells were pretreated with the metalloprotease inhibitor GM6001. Accordingly, GM6001 did not affect basal mobility of CX 3 CL1 (Fig. 6H) . In the presence of GM6001, TP similarly mobilized CX 3 CL1. The bleached area recovered to 55.5 Ϯ 3.5% by 1 min, significantly greater than the 27.7 Ϯ 2.5% recovery observed in the absence of TP stimulation (Fig.  6H , P Ͻ 0.001). At all time points after 20 s, TP facilitated recovery of fluorescence of plasmalemmal CX 3 CL1 (Fig. 6H , P Ͻ 0.03 at each point). Thus TP stimulation enhances lateral mobility of CX 3 CL1, which is normally tethered within the plasma membrane.
We directly examined whether TP stimulation promotes clustering of CX 3 CL1 at sites of contact with CX 3 CR1 on adherent leukocytes, by comparing the fluorescent signal of CX 3 CL1 at these contact points to that of CX 3 CL1 at adjacent sites where no leukocyte was tethered. We reasoned that TP stimulation could conceivably affect mobility of CX 3 CR1 receptor present on the surface of leukocytes, resulting in enhanced adhesion between these cells and CX 3 CL1-expressing cells. To selectively study the effects of TP stimulation on clustering of plasmalemmal CX 3 CL1, leukocytes were prefixed, effectively converting them to "beads" coated with CX 3 CR1 (4). After TP stimulation, the ratio of contact site CX 3 CL1 to non-contact site CX 3 CL1 was greater than in unstimulated cells (Fig. 6, I and J; control: 1.1 Ϯ 0.1 vs. TP stimulated: 1.7 Ϯ 0.2; Fig. 6K , P Ͻ 0.005). A ratio greater than one was seen in approximately one-half (46%) of unstimulated cells. After TP stimulation, 83% had a ratio greater than one, indicating clustering of CX 3 CL1. Collectively, these results demonstrate that TP stimulation promotes rapid shedding of plasmalemmal CX 3 CL1 but that despite decreased cell surface levels of the chemokine, CX 3 CL1-dependent adhesion of leukocytes is enhanced due to mobilization and clustering of the chemokine at contact sites with adherent leukocytes. In this manner, although net cell surface exposure of CX 3 CL1 is decreased, the overall avidity of interactions between leukocytes and CX 3 CL1 on the surface of adherent cells is actually strengthened.
DISCUSSION
The principal aim of this study was to examine regulation of CX 3 CL1 by TP. For these studies, we used CX 3 CL1-expressing ECV-304 cells and primary human vascular endothelial cells. Although derived from bladder epithelial carcinoma cells, ECV-304 cells have many endothelial features, including the propensity to grow in monolayers of flattened cells, formation of moderately tight intercellular junctions, and expression of the endothelial markers Flt-1 and von Willebrand factor (14, 16, 39) . Since the identification of CX 3 CL1, ECV-304 cells have been used extensively to study distribution, cleavage, and function of the chemokine, because the surface levels of CX 3 CL1 mirror those seen in cytokine-activated primary vascular endothelial cells and because expression of other cellular adhesion molecules is minimal (10, 17, 25, 43) . We previously showed that addition of a GFP tag alters neither distribution nor subcellular traffic of CX 3 CL1 (25) . To confirm the key findings of the current study, assays were performed using primary human vascular endothelial cells.
Overall exposure of CX 3 CL1 at the cell surface reflects the balance between shedding and recycling. Thus, in principle, the TP-induced decrease in CX 3 CL1 could result from 1) increased endocytosis, 2) decreased traffic of internalized CX 3 CL1 back to the plasma membrane, and/or 3) increased shedding from the cell surface. TP stimulation did not acutely alter recycling of the chemokine. Sustained TP stimulation (4 -24 h) has been shown to augment expression of the vascular adhesion molecules, intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin (19, 31) . The resultant increase reflected enhanced nuclear factor (NF)-B-dependent transcription and translation (19, 31) . ICAM-1 expression is significantly reduced in genetically targeted mice lacking TP, again illustrating the ability of TP to increase adhesion molecule expression over time (22) . Likewise, prolonged TP stimulation enhances expression of the chemokine CCL2 (monocyte chemoattractant protein-1, MCP-1), also through protein kinase C and NF-B (20) . To our knowledge, ours is the first study to examine how TP activation posttranslationally regulates cell surface exposure of an endothelial adhesion molecule or chemokine.
Blocking TACE, but not ADAM10, attenuated TP-induced shedding of CX 3 CL1 from the cell surface. Erk inhibition similarly blocked CX 3 CL1 shedding, consistent with studies demonstrating that TP engagement promotes protein kinase C activation and Erk phosphorylation (11, 30) . Erk, in turn, phosphorylates the cytoplasmic domain of TACE at Thr 735 and Ser 819 , thereby activating the protease (7, 9) . Blocking this phosphorylation prevents activation of TACE and ectodomain shedding of its biological substrates (7, 9) . Overall, our results demonstrate that TP stimulation causes rapid loss of CX 3 CL1 from the cell surface by promoting TACE-induced, but not 5 /well) were incubated with ECV-304 or ECV-CX3CL1-GFP monolayers under gentle rocking conditions (10 cycles/min) at 37°C for the times indicated. Nonadherent cells were removed by washing, and the remaining cells were fixed. Serial fields (ϫ63) were examined using a Leica deconvolution microscope, and the numbers of adherent cells were counted. Values are the mean (ϮSE) number of adherent K562-CX3CR1 cells from at least 3 experiments. *P Ͻ 0.01. ¶P Ͻ 0.02. B, top: confluent monolayers of human umbilical vein endothelial cells (HUVEC) were incubated with TNF-␣ (100 U/ml) for 4 h and then with IBOP for 30 min. Cell lysates were harvested, and immunoblotting was performed using anti-CX3CL1 and anti-actin Ab. Bottom, CX3CL1 band intensities were normalized to actin. Values are means Ϯ SE from 3 separate experiments. *P Ͻ 0.03. **P Ͻ 0.01. C: HUVEC were grown to confluence and stimulated with TNF-␣ as describe in B, followed by IBOP (0.1 g/ml for 30 min). In some instances, cells were incubated with U0126 (5 M) for 30 min before incubation with IBOP. Conditioned medium was collected and cell lysates were harvested. Protease inhibitor cocktail was added to conditioned medium and to cell lysis buffer to prevent protein degradation. Supernatants and cell lysates were cleared by centrifugation. With fresh samples, CX3CL1 was measured using a CX3CL1 ELISA kit. Values are means Ϯ SE of the fraction of soluble CX3CL1 released into the conditioned medium relative to the total amount of CX3CL1 (soluble and cell associated) from 3 separate experiments. *P Ͻ 0.002. **P Ͻ 0.0001. D: HUVEC were stimulated with TNF-␣, and adhesion assays were performed as described in A using K562 or K562-CX3CR1 cells. In some experiments, HUVEC were preincubated with blocking anti-CX3CL1 Ab (1 g/ml) for 30 min. The number of adherent leukocytes was normalized to the number of cells adherent to TNF-␣-stimulated HUVEC. Values are means Ϯ SE from 4 independent experiments. *P Ͻ 0.005. **P Ͻ 0.01. ***P Ͻ 0.05. E: adhesion assays were performed as described in C using freshly isolated human peripheral blood mononuclear cells (PBMC). Values are means Ϯ SE from 4 independent experiments. *P Ͻ 0.001. F: adhesion assays were performed as described in D using K562-CX3CR1 cells and TNF-␣-stimulated HUVEC. In some experiments, HUVEC were preincubated with U0126 (5 M for 30 min) or SQ29548 (10 M for 15 min) before incubation with IBOP. The number of adherent leukocytes was normalized to the number of cells adherent to TNF-␣-stimulated HUVEC. values are means Ϯ SE from 3 independent experiments. *P Ͻ 0.005. **P Ͻ 0.001. ADAM10-induced, shedding of CX 3 CL1, rather than by interfering with recycling of the chemokine.
Despite inducing proteolysis of approximately one-half the CX 3 CL1 present, TP augmented CX 3 CL1-dependent leukocyte adhesion. Although unexpected, this is not inconceivable, since the overall binding of CX 3 CR1 receptor on the leukocyte is determined by two distinct factors, namely, the density of CX 3 CL1 ligand present and the mobility of CX 3 CL1 within the plasma membrane. We hypothesized that TP stimulation must increase the avidity of remaining CX 3 CL1 for its receptor. In To prevent unwanted shedding of CX3CL1, in some wells ECV-CX3CL1-mCherry cells were preincubated with GM6001. To rule out potential effects of TP stimulation on cell surface clustering of CX3CR1, K562-CX3CR1 cells were first fixed using 4% paraformaldehyde and then washed with 100 mM glycine. At the end of the adhesion assay, cells were fixed and permeabilized, and K562-CX3CR1 cells were visualized by labeling with anti-BCR Ab and Alexa488-conjugated secondary Ab. Z-stack images are from spinning disk confocal microscopy (ϫ63). K: experiments were performed as described in I and J. XY or YZ dimensions of the Z-stack images were used to compare the localized fluorescence intensity of CX3CL1-mCherry at sites of interface with adherent K562-CX3CR1 cells with the signal in an adjacent, similar-size region in the plasma membrane, where no leukocyte was attached. With the use of ImageJ software, the ratio of fluorescent signal intensities between the site of contact and site of no contact was measured for 24 randomly chosen cells for each treatment condition. Values are means Ϯ SE from 3 separate experiments. *P Ͻ 0.005 vs. control.
principle, this could occur through mobilization of plasmalemmal CX 3 CL1 and subsequent clustering of the chemokine at points of contact with adherent leukocytes. Accordingly, plasmalemmal CX 3 CL1 was relatively immobile under basal conditions but became highly mobile following TP stimulation. We previously reported that plasmalemmal CX 3 CL1 is also immobile in other cell types under basal conditions (8) . TP stimulation promoted clustering of CX 3 CL1 at contact interfaces with bound leukocytes. Similarly, Kobayashi et al. (22) reported less leukocyte rolling and adherence in mice lacking TP, perhaps due to the absence of TP-induced clustering of CX 3 CL1 on the surface of the vascular wall. Our results are reminiscent of a study demonstrating that isoprostane iPF 2␣ -III, a known agonist of TP, enhances neutrophil adhesion to endothelial cells despite no increase in expression of endothelial adhesion molecules (1, 46) . Although the authors postulated that release of an unknown endothelial activating factor was responsible, isoprostane activation might also increase mobility of plasmalemmal adhesion molecules, thereby strengthening the avidity of interactions between neutrophils and endothelial cells.
Our results differ somewhat from those of Hundhausen et al. (17) , who reported that the synthetic phorbol ester PMA inhibited adhesion of THP-1 monocytic cells to CX 3 CL1-expressing adherent cells. Several possible explanations for this apparent discrepancy exist. First, THP-1 cells express other adhesion receptors whose levels and function may be modulated by PMA stimulation. In our study, we purposely used CX 3 CR1-expressing K562 cells, which do not express adhesion molecules such as L-selectin (10). Thus any adhesion observed was presumably attributable to interactions between leukocyte CX 3 CR1 and CX 3 CL1 on the surface of adherent cells. Stimulation by PMA and TP may have differential effects on the cell. TP receptors couple to G q /G 11 , with most functioning attributed to signaling via the ␣-rather than ␤␥-subunits (21) . Thus stimulation by PMA or TP can activate phospholipase C, generating inositol triphosphate (IP 3 ) and diacylglycerol (DAG), increasing intracellular calcium concentration, and activating protein kinase C (21) . In primary human cells, TP also couples to G i and to G 12/13 and is linked to cAMP (15, 21) . Thus the TP receptor has the potential to utilize at least four distinct intracellular signaling pathways. Mobilization of CX 3 CL1 by TP may reflect activation of these pathways. In our study, TP activation consistently increased CX 3 CL1-dependent leukocyte adhesion, even to primary human vascular endothelial cells expressing endogenous CX 3 CL1, highlighting the physiologic relevance of these observations. This is the first description of regulation of CX 3 CL1 exposure and mobility by a G protein-coupled receptor.
An intriguing question is how CX 3 CL1 is anchored to the plasma membrane in the first place. Previously, we reported that CX 3 CL1 does not directly interact with the actin cytoskeleton (8) . Recent work has demonstrated an integral role for dendritic cell (DC) CX 3 CL1 in the accumulation of lipid rafts at DC-NK cell synapses (34) . However, we found that in adherent cells, plasmalemmal CX 3 CL1 does not associate with lipid rafts and, accordingly, that cholesterol depletion does not alter the mobility of the chemokine (8) . Future studies are needed to investigate 1) whether CX 3 CL1 indirectly associates with the actin cytoskeleton by one or more Triton-soluble adaptor proteins, 2) whether CX 3 CL1 is "fenced" into discrete regions of the membrane, and 3) precisely how TP uncouples CX 3 CL1 from its membrane anchor (33, 38) .
TP plays a complex role in vascular inflammation. Given the timeframe of events that we investigated, it appears that early in the inflammatory cascade, TP stimulation induces shedding of endothelial CX 3 CL1 to release the soluble chemoattractant species, thereby recruiting circulating leukocytes. Slightly later, the balance is subtly altered to facilitate adhesion of leukocytes thus recruited to the area of vascular injury. Regulation of CX 3 CL1 by TP in this manner may represent a link, heretofore unexplored, between the events accompanying the platelet aggregation and activation and those accompanying the vascular inflammation that, collectively, contribute to atherogenesis. The dynamic interplay among these individual events in vivo remains to be elucidated.
